Page 4 - Mark Neumann News Today

Miramar Capital LLC grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 2.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,550 shares of the biopharmaceutical company’s stock after acquiring an additional 555 shares during […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Tuesday, Benzinga reports. They currently have a $98.00 price objective on the biopharmaceutical company’s stock. Several other analysts have also commented on the stock. Royal Bank of Canada lifted their price objective on shares of […]

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. ITCI has been the subject of several other research reports. Royal Bank of Canada increased their price target on Intra-Cellular Therapies from […]

StockNews.com downgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) from a buy rating to a hold rating in a research report sent to investors on Tuesday. A number of other research analysts have also recently weighed in on ITCI. Morgan Stanley reaffirmed an overweight rating and set a $80.00 price target on shares of […]

Pier Capital LLC grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 147,896 shares of the biopharmaceutical company’s stock after purchasing an additional 5,155 shares during the quarter. Intra-Cellular Therapies comprises 1.2% of Pier Capital LLC’s portfolio, making the stock […]

This weekend breweries, vineyards, and other local businesses will be making extra money by letting nascar fans traveling via RV or motorhome stay overnight on their premises.

StockNews.com upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) from a hold rating to a buy rating in a research note issued to investors on Monday. Several other brokerages have also recently issued reports on ITCI. Mizuho lifted their target price on Intra-Cellular Therapies from $74.00 to $76.00 in a research report on Monday, […]

Operator: Good morning. And welcome to Intra-Cellular Therapies Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

La Crosses Common Council approving a number of items on Thursdays agenda. Including the amended ordinance to designate areas of city-owned properties, like parks, as no camping zones.

Stonnington Group LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 164.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,200 shares of the biopharmaceutical company’s stock after acquiring an additional 8,200 shares during the period. Stonnington Group […]